Literature DB >> 31811061

Assessing PET Parameters in Oncologic 18F-FDG Studies.

Ismet Sarikaya1, Ali Sarikaya2.   

Abstract

PET imaging, particularly oncologic applications of 18F-FDG, has become a routine diagnostic study. To better describe malignancies, various PET parameters are used. In 18F-FDG PET studies, SUVmax is the most commonly used parameter to measure the metabolic activity of the tumor. In obese patients, SUV corrected by lean body mass (SUL), and in pediatric patients, SUV corrected by body surface area, are recommended. Metabolic tumor volume is an important parameter to determine the local and total tumor burden. Total lesion glycolysis (SUVmean × metabolic tumor volume) provides information about averages. Some treatment response assessment protocols recommend using the SUVpeak or SULpeak of the tumor. Tumor-to-liver ratio and tumor-to-blood-pool ratio are helpful when comparing studies for treatment response assessment. Dual-time-point PET imaging with retention index can help differentiate malignant from benign lesions and may help detect small lesions. Dynamic 18F-FDG PET imaging and quantitative analysis can measure the metabolic, phosphorylation, and dephosphorylation rates of lesions but are mainly used for research purposes. In this article, we will review the currently available PET parameters in 18F-FDG studies with their importance, uses, limitations, and reasons for erroneous results.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-FDG; PET; SUV; oncology; parameter

Mesh:

Substances:

Year:  2019        PMID: 31811061     DOI: 10.2967/jnmt.119.236109

Source DB:  PubMed          Journal:  J Nucl Med Technol        ISSN: 0091-4916


  7 in total

1.  Preoperative 2-[18F]FDG PET-CT aids in the prognostic stratification for patients with primary ampullary carcinoma.

Authors:  Pei-Ju Chuang; Hsiu-Po Wang; Yu-Jen Lin; Chieh-Chang Chen; Yu-Wen Tien; Min-Shu Hsieh; Shih-Hung Yang; Ruoh-Fang Yen; Chi-Lun Ko; Yen-Wen Wu; Mei-Fang Cheng
Journal:  Eur Radiol       Date:  2021-04-17       Impact factor: 5.315

2.  eIF6 is potential diagnostic and prognostic biomarker that associated with 18F-FDG PET/CT features and immune signatures in esophageal carcinoma.

Authors:  Yan Gao; Lingling Yuan; Jing Zeng; Fuyan Li; Xiaohui Li; Fan Tan; Xusheng Liu; Huabing Wan; Xueyan Kui; Xiaoyu Liu; Changbin Ke; Zhijun Pei
Journal:  J Transl Med       Date:  2022-07-06       Impact factor: 8.440

3.  Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?

Authors:  Gundula Rendl; Gregor Schweighofer-Zwink; Stefan Sorko; Hans-Jürgen Gallowitsch; Wolfgang Hitzl; Diana Reisinger; Christian Pirich
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

Review 4.  Emerging role of 18F-FDG PET/CT in Castleman disease: a review.

Authors:  Benjamin Koa; Austin J Borja; Mahmoud Aly; Sayuri Padmanabhan; Joseph Tran; Vincent Zhang; Chaitanya Rojulpote; Sheila K Pierson; Mark-Avery Tamakloe; Johnson S Khor; Thomas J Werner; David C Fajgenbaum; Abass Alavi; Mona-Elisabeth Revheim
Journal:  Insights Imaging       Date:  2021-03-11

5.  18F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis-The Central Role of Volume.

Authors:  James C Reynolds; Roberto Maass-Moreno; Anish Thomas; Alexander Ling; Emerson B Padiernos; Seth M Steinberg; Raffit Hassan
Journal:  J Nucl Med       Date:  2020-04-13       Impact factor: 11.082

6.  Systematic Evaluation of Kinetics and Distribution of Muscle and Lymph Node Activation Measured by 18F-FDG- and 11C-PBR28-PET/CT Imaging, and Whole Blood and Muscle Transcriptomics After Immunization of Healthy Humans With Adjuvanted and Unadjuvanted Vaccines.

Authors:  Zarni Win; January Weiner Rd; Allan Listanco; Neva Patel; Rohini Sharma; Aldona Greenwood; Jeroen Maertzdorf; Hans-Joachim Mollenkopf; Kat Pizzoferro; Thomas Cole; Caroline L Bodinham; Stefan H E Kaufmann; Philippe Denoel; Giuseppe Del Giudice; David J M Lewis
Journal:  Front Immunol       Date:  2021-02-05       Impact factor: 7.561

7.  Influencing Factors and Prognostic Value of 18F-FDG PET/CT Metabolic and Volumetric Parameters in Non-Small Cell Lung Cancer.

Authors:  Lixia Zhang; Zhe Ren; Caiyun Xu; Qiushuang Li; Jinyan Chen
Journal:  Int J Gen Med       Date:  2021-07-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.